| abstract |
FIELD: biotechnology.SUBSTANCE: described is a compound for use in therapy, which is a polypeptide having a half-life expressed as t1/2-beta in a human for at least 3 days. Polypeptide contains a single immunoglobulin variable domain (ISV) at its C-terminal, wherein the said ISV is either VHH optimized by the VHH sequence, humanised VHH or camellated VH or is ISV, which is based on the VH (one) domain antibody based on VH dAb™ or based on the VH microbody. ISV has a C-terminal VTVSS(X)sequence, where n = 1, 2 or 3, in which each X = Ala or Gly; or n = 1, 2 or 3, in which each X = Ala; or n = 1, 2 or 3, in which each X = Gly; or n = 2 or 3, wherein at least one X = Ala or Gly; or n = 2 or 3, wherein all except one X = Ala or Gly. Polypeptide also contains a peptide which binds serum albumin or a serum albumin binding domain.EFFECT: invention enables solving the problem of protein interference in ADA-analysis.22 cl, 9 dwg, 12 tbl, 9 ex |